News Hims & Hers buys Zava to form European beachhead US telehealth company Hims & Hers has reached a deal to buy its UK counterpart Zava as part of a broader push into Europe.
News Novo Nordisk unleashes Wegovy telehealth blitz Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.
News Compounders cast adrift after semaglutide shortage ends The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.
News Pharma group slams Hims & Hers over Super Bowl GLP-1 ad Partnership for Safe Medicines claims the Hims & Hers ad for compounded weight-loss drug semaglutide, due to run during the Super Bowl, is "reckless."
Oncology Breaking barriers to CAR T-cell therapy: The vision for expa... Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
